On October 26 and 27, ALS Quebec joined organizations and members of the ALS community from across the country for two days of advocacy in Ottawa. The goal: to call for a federal investment of $50 million over five years in the Canadian Collaboration to Cure ALS. 

Since then, the 2026 federal budget has been tabled, and it does not include this investment. Our request remains unchanged, and we will continue to champion it with the ALS community and our partners. 

Two days of advocacy on Parliament Hill 

More than 40 delegates (people living with ALS, caregivers, clinicians, researchers and ambassadors) met with Members of Parliament and senators to share the reality of life with ALS. Speaking with one voice, they reminded elected officials that today’s decisions will have a real impact on the lives of thousands of Canadians touched by ALS. 

Quebec Delegation

From left to right: Isabelle Lessard and her daughter Charline Bourque; Claudine Cook, Executive Director of ALS Quebec; Anaïs Le Bourdon, Director of Communications at ALS Quebec; Dr. Alec Cooper; Marie-Hélène Gaudreault, Co-Chair of the ALS Caucus; Norman MacIsaac; Marie-Christine Tremblay; Susan Kennerknecht, Chair of the Board of Directors of ALS Quebec; Spencer Levine and Amanda Tam; Dr. Richard Robitaille 

Why this request can’t wait 

Nearly 4,000 Canadians are living with ALS, including 600 in Quebec. Each year, about 1,000 new diagnoses are made across the country, 200 of them in Quebec, and about as many people die from the disease: for every new diagnosis, one person dies. With a life expectancy of only two to five years after diagnosis, people living with ALS cannot afford to wait. 

ALS also affects veterans. As Canada increases its defense spending, the ALS community is asking the federal government to recognize that support for those who serve the country must continue well beyond their years of service. Veterans are at higher risk of receiving an ALS diagnosis, and researchers still do not know why. 

Our request: $50 million for the Canadian Collaboration to Cure ALS 

We continue to advocate for a federal investment of $50 million over five years. This national strategy would expand four promising, donor-funded research initiatives: 

  • CAPTURE ALS: a pan-Canadian open science platform that collects clinical, genomic and biological data. 
  • Access ALS: an initiative that expands Canadians’ access to ALS clinical trials and encourages pharmaceutical partners to develop new treatments. 

This investment targets three urgent priorities: 

  • Accelerate Canadian research on the possible causes of ALS, including why military members and veterans are at higher risk. 
  • Expand access to clinical trials, so that more Canadians living with ALS can access promising therapies, no matter where they live. 
  • Strengthen national data collection, to give researchers the information they need to better understand ALS, improve care and speed up discoveries. 

Why advocacy is essential 

Advocacy turns individual experiences into concrete action that shapes care, access to services and treatments, and quality of life. By working with our partners, government bodies and the ALS community, we make sure the lived realities of our community guide today’s decisions and help build lasting solutions. 

Share this article.